LT3500564T - Diacilglicerolio aciltransferazės 2 inhibitoriai - Google Patents

Diacilglicerolio aciltransferazės 2 inhibitoriai

Info

Publication number: LT3500564T
Authority: LT; Lithuania
Prior art keywords: inhibitors; diacylglycerol acyltransferase; acyltransferase; diacylglycerol
Prior art date: 2016-08-19

Application number

LTEP17761332.0T

Other languages

English (en)

Inventor

Markus Boehm

Shawn Cabral

Matthew S. Dowling

Kentaro Futatsugi

Kim HUARD

Esther Cheng Yin LEE

Qifang Li

Allyn T. Londregan

Jana Polivkova

David A. Price

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-08-19

Filing date

2017-08-09

Publication date

2020-12-28

2017-08-09 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

2020-12-28 Publication of LT3500564T publication Critical patent/LT3500564T/lt

Links

102100027840 Acyl-CoA wax alcohol acyltransferase 1 Human genes 0.000 title 1
101000698136 Homo sapiens Acyl-CoA wax alcohol acyltransferase 1 Proteins 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Immunology (AREA)
Child & Adolescent Psychology (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)

LTEP17761332.0T 2016-08-19 2017-08-09 Diacilglicerolio aciltransferazės 2 inhibitoriai LT3500564T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662377137P	2016-08-19	2016-08-19
PCT/IB2017/054862 WO2018033832A1 (en)	2016-08-19	2017-08-09	Diacylglycerol acyltransferase 2 inhibitors

Publications (1)

Publication Number	Publication Date
LT3500564T true LT3500564T (lt)	2020-12-28

Family

ID=59762015

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP17761332.0T LT3500564T (lt)	2016-08-19	2017-08-09	Diacilglicerolio aciltransferazės 2 inhibitoriai

Country Status (44)

Country	Link
US (5)	US10071992B2 (lt)
EP (1)	EP3500564B1 (lt)
JP (1)	JP6657473B2 (lt)
KR (1)	KR102225925B1 (lt)
CN (1)	CN109641875B (lt)
AR (1)	AR109179A1 (lt)
AU (1)	AU2017313420B2 (lt)
BR (1)	BR112019001976A2 (lt)
CA (1)	CA2976690A1 (lt)
CL (1)	CL2019000406A1 (lt)
CO (1)	CO2019001421A2 (lt)
CR (1)	CR20190085A (lt)
CU (1)	CU24507B1 (lt)
CY (1)	CY1123679T1 (lt)
DK (1)	DK3500564T3 (lt)
DO (1)	DOP2019000032A (lt)
EA (1)	EA037476B1 (lt)
EC (1)	ECSP19012670A (lt)
ES (1)	ES2834060T3 (lt)
GE (1)	GEP20207159B (lt)
HR (1)	HRP20201748T1 (lt)
HU (1)	HUE051731T2 (lt)
IL (1)	IL264818B (lt)
LT (1)	LT3500564T (lt)
MA (1)	MA45985B1 (lt)
MD (1)	MD3500564T2 (lt)
MX (1)	MX370766B (lt)
MY (1)	MY196330A (lt)
NI (1)	NI201900012A (lt)
PE (1)	PE20190518A1 (lt)
PH (1)	PH12019500349A1 (lt)
PL (1)	PL3500564T3 (lt)
PT (1)	PT3500564T (lt)
RS (1)	RS61141B1 (lt)
RU (1)	RU2719589C1 (lt)
SG (1)	SG11201900490WA (lt)
SI (1)	SI3500564T1 (lt)
SV (1)	SV2019005823A (lt)
TN (1)	TN2019000036A1 (lt)
TW (1)	TWI688560B (lt)
UA (1)	UA122100C2 (lt)
UY (1)	UY37366A (lt)
WO (1)	WO2018033832A1 (lt)
ZA (1)	ZA201900516B (lt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR109179A1 (es) *	2016-08-19	2018-11-07	Pfizer	Inhibidores de diacilglicerol aciltransferasa 2
EP3743092A4 (en)	2018-01-23	2021-10-20	Gila Therapeutics, Inc.	PHARMACEUTICAL PEPTIDE-YY FORMULATIONS, COMPOSITIONS, AND PROCEDURES
EP3765034A1 (en)	2018-03-12	2021-01-20	Yeda Research and Development Co. Ltd	Treatment of a heart disease
CA3045644C (en)	2018-06-13	2024-01-16	Pfizer Inc.	Glp-1 receptor agonists and uses thereof
AU2019329884B2 (en) *	2018-08-31	2022-01-27	Pfizer Inc.	Combinations for treatment of NASH/NAFLD and related diseases
RU2706026C1 (ru) *	2018-12-28	2019-11-13	Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр им. А.С. Логинова Департамента здравоохранения города Москвы	Способ лечения неалкогольной жировой болезни печени и сахарного диабета второго типа
CN113874019A (zh)	2019-05-20	2021-12-31	辉瑞大药厂	用于治疗nash/nafld及相关疾病的包含作为glp-1r激动剂的苯并二氧杂环戊烯的组合
TWI771766B (zh)	2019-10-04	2022-07-21	美商輝瑞股份有限公司	二醯基甘油醯基轉移酶２抑制劑
BR112022010599A2 (pt)	2019-12-10	2022-08-16	Pfizer	Formas sólidas de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico, sal de 1,3-dihidróxi-2-(hidroximetil)propan-2-amina
PE20221630A1 (es) *	2019-12-23	2022-10-19	Lg Chemical Ltd	Derivado de amino arilo novedoso util como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo
CA3161640A1 (en) *	2019-12-23	2021-07-01	Seung Hyun Yoon	Novel amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof
WO2021161222A1 (en) *	2020-02-11	2021-08-19	Inorbit Therapeutics Ab	Compounds useful in inhibiting diacylglycerol o-acyltransferase and methods of making and using the same
JP2022058085A (ja)	2020-02-24	2022-04-11	ファイザー・インク	ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
JP2021134211A (ja) *	2020-02-24	2021-09-13	ファイザー・インク	Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
IL296694A (en)	2020-03-27	2022-11-01	Pfizer	Treatment of type 2 diabetes, obesity or excess weight using 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[( 2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or its pharmaceutical salts
US11478533B2 (en)	2020-04-27	2022-10-25	Novo Nordisk A/S	Semaglutide for use in medicine
EP4153584A1 (en)	2020-05-18	2023-03-29	Merck Sharp & Dohme LLC	Novel diacylglyceride o-acyltransferase 2 inhibitors
CN116113635A (zh)	2020-06-09	2023-05-12	辉瑞公司	作为黑皮质素4受体拮抗剂的螺环化合物及其用途
TWI817191B (zh) *	2020-09-04	2023-10-01	南韓商Ｌｇ化學股份有限公司	新穎聯芳基衍生物及其作為針對二醯基甘油醯基轉移酶２之抑制劑之用途
TW202229243A (zh)	2020-10-08	2022-08-01	美商默沙東藥廠	作為新穎二醯基甘油酯o-醯基轉移酶2抑制劑之苯并咪唑酮衍生物的製備
CN112972654B (zh) *	2021-03-05	2022-07-01	温州医科大学慈溪生物医药研究院	Fgf21在制备治疗脑神经损伤的药物中的应用
WO2023026180A1 (en)	2021-08-26	2023-03-02	Pfizer Inc.	Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
CA3230347A1 (en)	2021-08-31	2023-03-09	Pfizer Inc.	Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt
AU2022403203A1 (en) *	2021-12-01	2024-05-02	Pfizer Inc.	3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
WO2023105387A1 (en)	2021-12-06	2023-06-15	Pfizer Inc.	Melanocortin 4 receptor antagonists and uses thereof
WO2023169456A1 (en)	2022-03-09	2023-09-14	Gasherbrum Bio , Inc.	Heterocyclic glp-1 agonists
WO2023198140A1 (en)	2022-04-14	2023-10-19	Gasherbrum Bio, Inc.	Heterocyclic glp-1 agonists
WO2023228023A1 (en)	2022-05-23	2023-11-30	Pfizer Inc.	Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof
CN115089590B (zh) *	2022-06-13	2023-05-12	同济大学	环戊基***嘧啶类药物作为药物成分在肝炎药物中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1146866A (en)	1979-07-05	1983-05-24	Yamanouchi Pharmaceutical Co. Ltd.	Process for the production of sustained release pharmaceutical composition of solid medical material
EP0028489B1 (en)	1979-11-05	1983-10-05	Beecham Group Plc	Enzyme derivatives, and their preparation
DE3438830A1 (de)	1984-10-23	1986-04-30	Rentschler Arzneimittel	Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
ES2111065T5 (es)	1991-04-16	2005-06-16	Nippon Shinyaku Company, Limited	Procedimiento para producir una dispersion solida.
US5340591A (en)	1992-01-24	1994-08-23	Fujisawa Pharmaceutical Co., Ltd.	Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja)	1992-03-12	2002-03-11	大正製薬株式会社	経口製剤用組成物
US5612359A (en)	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
DE19504832A1 (de)	1995-02-14	1996-08-22	Basf Ag	Feste Wirkstoff-Zubereitungen
TW536540B (en)	1997-01-30	2003-06-11	Bristol Myers Squibb Co	Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
ATE364374T1 (de)	1997-08-11	2007-07-15	Pfizer Prod Inc	Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
CA2336714A1 (en)	1998-07-06	2000-01-13	Bristol-Myers Squibb Company	Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
MY125533A (en)	1999-12-06	2006-08-30	Bristol Myers Squibb Co	Heterocyclic dihydropyrimidine compounds
GEP20053710B (en)	2001-02-28	2005-12-26	Merck & Co Inc	Acylated Piperidine Derivatives as Melanocortin-4 Receptor Agonists
CN1642599A (zh)	2002-02-27	2005-07-20	辉瑞产品公司	Acc抑制剂
ATE437870T1 (de)	2004-05-12	2009-08-15	Pfizer Prod Inc	Prolinderivate und deren verwendung als dipeptidylpeptidase-iv-inhibitoren
UA84208C2 (en)	2004-05-25	2008-09-25	Пфайзер Продактс Инк.	Tetraazabenzo(e)azulene derivatives and analogs thereof
PA8660701A1 (es)	2005-02-04	2006-09-22	Pfizer Prod Inc	Agonistas de pyy y sus usos
ES2487967T3 (es)	2006-04-20	2014-08-25	Pfizer Products Inc.	Compuestos amido heterocíclicos condensados con fenilo para la prevención y el tratamiento de enfermedades mediadas por la glucoquinasa
BRPI0721053A2 (pt)	2006-11-29	2014-07-29	Pfizer Prod Inc	INIBIDORES DE ESPIROCETONA ACETIL-CoA CARBOXILASE
US20090036425A1 (en)	2007-08-02	2009-02-05	Pfizer Inc	Substituted bicyclolactam compounds
CA2724603A1 (en)	2008-05-28	2009-12-03	Pfizer Inc.	Pyrazolospiroketone acetyl-coa carboxylase inhibitors
JP5435592B2 (ja)	2008-05-28	2014-03-05	ファイザー・インク	ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
JP2011529483A (ja)	2008-07-29	2011-12-08	ファイザー・インク	フッ素化ヘテロアリール
CN102149717B (zh)	2008-08-28	2014-05-14	辉瑞大药厂	二氧杂-双环[3.2.1]辛烷-2，3，4-三醇衍生物
WO2010077861A1 (en)	2008-12-17	2010-07-08	Via Pharmaceuticals, Inc	Inhibitors of diacylglycerol aclytransferase
TW201038580A (en)	2009-02-02	2010-11-01	Pfizer	4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
US20110319379A1 (en)	2009-03-11	2011-12-29	Corbett Jeffrey W	Substituted Indazole Amides And Their Use As Glucokinase Activators
PT2406253E (pt)	2009-03-11	2013-09-11	Pfizer	Derivados de benzofuranilo utilizados como inibidores de glucocinase
WO2010106457A2 (en)	2009-03-20	2010-09-23	Pfizer Inc.	3-oxa-7-azabicyclo[3.3.1]nonanes
WO2010128414A1 (en)	2009-05-08	2010-11-11	Pfizer Inc.	Gpr 119 modulators
EP2427450A1 (en)	2009-05-08	2012-03-14	Pfizer Inc.	Gpr 119 modulators
SG175995A1 (en)	2009-06-05	2011-12-29	Pfizer	L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (en)	2009-07-09	2011-01-13	Merck Sharp & Dohme Corp.	Neuromedin u receptor agonists and uses thereof
CA2852609C (en) *	2011-11-29	2020-03-10	F. Hoffmann-La Roche Ag	Aminopyrimidine derivatives as lrrk2 modulators
WO2013137628A1 (ko)	2012-03-16	2013-09-19	한국생명공학연구원	신규한 디아실글리세롤 아실트랜스퍼레이즈 2 억제 물질 및 이의 이용
EP2834238B1 (en)	2012-04-06	2017-02-01	Pfizer Inc.	Diacylglycerol acyltransferase 2 inhibitors
AU2014233411B2 (en) *	2013-03-15	2018-09-13	Deciphera Pharmaceuticals, Llc	2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities
AR098394A1 (es)	2013-11-25	2016-05-26	Lilly Co Eli	Inhibidores de dgat2 (diacilglicerol o-aciltransferasa 2)
MA39753B1 (fr) *	2014-03-17	2018-10-31	Pfizer	Inhibiteurs de diacylglycérol acyltransférase pour le traitement de troubles métaboliques ou analogues
US10568876B2 (en)	2014-09-05	2020-02-25	Merck Sharp & Dohme Corp.	Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
US9877957B2 (en)	2014-09-05	2018-01-30	Merck Sharp & Dohme Corp.	Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
EP3188731B1 (en)	2014-09-05	2019-04-03	Merck Sharp & Dohme Corp.	Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
AR109179A1 (es) *	2016-08-19	2018-11-07	Pfizer	Inhibidores de diacilglicerol aciltransferasa 2
US10017992B2 (en)	2016-11-04	2018-07-10	Ashmin Holding Llc	Radial ball bearing and method

2017
- 2017-07-27 AR ARP170102125A patent/AR109179A1/es unknown
- 2017-08-09 CU CU2019000003A patent/CU24507B1/es unknown
- 2017-08-09 MA MA45985A patent/MA45985B1/fr unknown
- 2017-08-09 JP JP2019508858A patent/JP6657473B2/ja active Active
- 2017-08-09 CN CN201780050709.4A patent/CN109641875B/zh active Active
- 2017-08-09 UA UAA201900751A patent/UA122100C2/uk unknown
- 2017-08-09 EP EP17761332.0A patent/EP3500564B1/en active Active
- 2017-08-09 LT LTEP17761332.0T patent/LT3500564T/lt unknown
- 2017-08-09 DK DK17761332.0T patent/DK3500564T3/da active
- 2017-08-09 PE PE2019000392A patent/PE20190518A1/es unknown
- 2017-08-09 GE GEAP201715005A patent/GEP20207159B/en unknown
- 2017-08-09 BR BR112019001976-6A patent/BR112019001976A2/pt active Search and Examination
- 2017-08-09 PL PL17761332T patent/PL3500564T3/pl unknown
- 2017-08-09 SI SI201730499T patent/SI3500564T1/sl unknown
- 2017-08-09 TN TNP/2019/000036A patent/TN2019000036A1/en unknown
- 2017-08-09 RU RU2019104413A patent/RU2719589C1/ru active
- 2017-08-09 ES ES17761332T patent/ES2834060T3/es active Active
- 2017-08-09 MX MX2019001872A patent/MX370766B/es active IP Right Grant
- 2017-08-09 HU HUE17761332A patent/HUE051731T2/hu unknown
- 2017-08-09 WO PCT/IB2017/054862 patent/WO2018033832A1/en unknown
- 2017-08-09 AU AU2017313420A patent/AU2017313420B2/en active Active
- 2017-08-09 MD MDE20190711T patent/MD3500564T2/ro unknown
- 2017-08-09 MY MYPI2019000769A patent/MY196330A/en unknown
- 2017-08-09 RS RS20201375A patent/RS61141B1/sr unknown
- 2017-08-09 PT PT177613320T patent/PT3500564T/pt unknown
- 2017-08-09 EA EA201990202A patent/EA037476B1/ru unknown
- 2017-08-09 CR CR20190085A patent/CR20190085A/es unknown
- 2017-08-09 KR KR1020197007312A patent/KR102225925B1/ko active IP Right Grant
- 2017-08-09 SG SG11201900490WA patent/SG11201900490WA/en unknown
- 2017-08-11 US US15/674,914 patent/US10071992B2/en active Active
- 2017-08-16 CA CA2976690A patent/CA2976690A1/en active Pending
- 2017-08-16 TW TW106127806A patent/TWI688560B/zh active
- 2017-08-17 UY UY0001037366A patent/UY37366A/es not_active Application Discontinuation
2018
- 2018-05-11 US US15/977,238 patent/US20180258081A1/en not_active Abandoned
2019
- 2019-01-24 ZA ZA201900516A patent/ZA201900516B/en unknown
- 2019-01-31 SV SV2019005823A patent/SV2019005823A/es unknown
- 2019-02-11 NI NI201900012A patent/NI201900012A/es unknown
- 2019-02-13 IL IL264818A patent/IL264818B/en active IP Right Grant
- 2019-02-14 CL CL2019000406A patent/CL2019000406A1/es unknown
- 2019-02-15 DO DO2019000032A patent/DOP2019000032A/es unknown
- 2019-02-18 CO CONC2019/0001421A patent/CO2019001421A2/es unknown
- 2019-02-19 PH PH12019500349A patent/PH12019500349A1/en unknown
- 2019-02-20 EC ECSENADI201912670A patent/ECSP19012670A/es unknown
2020
- 2020-02-18 US US16/793,441 patent/US11034678B2/en active Active
- 2020-10-29 HR HRP20201748TT patent/HRP20201748T1/hr unknown
- 2020-11-04 CY CY20201101042T patent/CY1123679T1/el unknown
2021
- 2021-06-11 US US17/345,064 patent/US11866425B2/en active Active
2023
- 2023-11-28 US US18/520,638 patent/US20240140937A1/en active Pending

Also Published As

Publication number	Publication date
CN109641875A (zh)	2019-04-16
AU2017313420B2 (en)	2020-12-24
EA037476B1 (ru)	2021-04-01
ECSP19012670A (es)	2019-03-29
NI201900012A (es)	2019-04-08
PE20190518A1 (es)	2019-04-10
RS61141B1 (sr)	2020-12-31
SG11201900490WA (en)	2019-03-28
MX2019001872A (es)	2019-06-13
US20180258081A1 (en)	2018-09-13
ES2834060T3 (es)	2021-06-16
GEP20207159B (en)	2020-10-12
IL264818B (en)	2021-05-31
CN109641875B (zh)	2021-08-31
CA2976690A1 (en)	2018-02-19
RU2719589C1 (ru)	2020-04-21
US20210309646A1 (en)	2021-10-07
MA45985A (fr)	2019-06-26
PL3500564T3 (pl)	2021-04-06
KR102225925B1 (ko)	2021-03-09
US20180051012A1 (en)	2018-02-22
UY37366A (es)	2018-03-23
WO2018033832A1 (en)	2018-02-22
EA201990202A1 (ru)	2019-07-31
US10071992B2 (en)	2018-09-11
MA45985B1 (fr)	2020-10-28
MY196330A (en)	2023-03-24
AU2017313420A1 (en)	2019-02-07
DOP2019000032A (es)	2019-04-15
HUE051731T2 (hu)	2021-03-29
MD3500564T2 (ro)	2020-12-31
TWI688560B (zh)	2020-03-21
TW201819366A (zh)	2018-06-01
JP6657473B2 (ja)	2020-03-04
ZA201900516B (en)	2019-10-30
SI3500564T1 (sl)	2021-01-29
PT3500564T (pt)	2020-11-25
MX370766B (es)	2019-12-17
US20200181127A1 (en)	2020-06-11
CU20190003A7 (es)	2019-09-04
CO2019001421A2 (es)	2019-03-08
BR112019001976A2 (pt)	2019-05-07
CL2019000406A1 (es)	2019-07-05
US11034678B2 (en)	2021-06-15
KR20190035897A (ko)	2019-04-03
US20240140937A1 (en)	2024-05-02
PH12019500349A1 (en)	2019-12-16
HRP20201748T1 (hr)	2020-12-25
CU24507B1 (es)	2021-04-07
EP3500564A1 (en)	2019-06-26
JP2019524831A (ja)	2019-09-05
SV2019005823A (es)	2019-03-19
US11866425B2 (en)	2024-01-09
TN2019000036A1 (en)	2020-07-15
UA122100C2 (uk)	2020-09-10
CY1123679T1 (el)	2022-03-24
AR109179A1 (es)	2018-11-07
CR20190085A (es)	2019-05-09
DK3500564T3 (da)	2020-10-19
EP3500564B1 (en)	2020-10-07

Publication	Publication Date	Title
IL264818B (en)	2021-05-31	Diacylglycerol acyltransferase 2 inhibitors
IL264687B (en)	2021-04-29	cdk2/4/6 pyridopyrimidinone inhibitors
IL283267A (en)	2021-07-29	Inhibitors of menin–mll interaction
PL3512850T3 (pl)	2023-10-09	Inhibitory interakcji menina-mll
GB201521134D0 (en)	2016-01-13	Privitar case 1
IL265139B (en)	2021-08-31	Dopamine-b-hydroxylase inhibitors
GB201612860D0 (en)	2016-09-07	Inhibitors
PL3408451T3 (pl)	2020-05-18	Zakrętarka
GB2559511B (en)	2022-03-02	Improved knock box
HK1257566A1 (zh)	2019-10-25	Bace1抑制劑
GB2558849B (en)	2019-03-20	Music box device
GB2557668B (en)	2020-02-26	Box
GB201619435D0 (en)	2017-01-04	Fft 1
GB201710604D0 (en)	2017-08-16	RedCloud BB3
GB201621147D0 (en)	2017-01-25	Tidysqueeze 5
AP00907S1 (en)	2017-05-30	Box
AP00908S1 (en)	2017-05-30	Box
AU201615296S (en)	2016-12-06	Refrigerator box
GB201521588D0 (en)	2016-01-20	Fft 1
AU5457P (en)	2016-01-25	JOAe 6656 Aeonium arborium
GB201607697D0 (en)	2016-06-15	OverTyre 1
GB201601798D0 (en)	2016-03-16	Rollette 2
GB201600933D0 (en)	2016-03-02	Pantrap 2016
GB201600134D0 (en)	2016-02-17	Effective hole expansion screw
GB201513238D0 (en)	2015-09-09	The aspect of pin-number analysing box